HRMY Harmony Biosciences Holdings, Inc.
USHealthcareAs of 2026-07-10 13:12
Why HRMY matters now
Harmony Biosciences Holdings, Inc. (HRMY) is a US stock in Healthcare. The latest InvestLog snapshot shows $36.41 with -4.71% on the session and $2.11B in market capitalization; recent performance reads 1-month +9.33% and YTD -11.06%.
The latest financial table shown here is Q1 2026, with revenue of $215.4M, net income of $32.5M, and EPS of $0.55. Investors can compare that operating picture with valuation signals such as P/E 10.53 and FCF yield 17.7%.
The latest indexable market news headline is "Is HRMY Stock Worth Buying With Neutral Signals and Cheap Valuation?" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Hold with a median target of $45.50; recent insider activity includes Sender Gary filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
10.53
PEG
1.16
P/B
2.11
P/S
2.14
EV/EBITDA
6.62
DCF Value
$115.91
FCF Yield
17.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
76.5%
Operating Margin
21.1%
Net Margin
16.2%
ROE
17.2%
ROA
11.4%
ROIC
12.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $215.4M | $32.5M | $0.55 |
| Q4 2025 | $243.8M | $22.5M | $0.38 |
| FY 2025 | $868.5M | $158.7M | $2.71 |
| Q3 2025 | $239.5M | $50.9M | $0.87 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$43.00
Target (Median)
$45.50
Target Range
$31.00 - $50.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.97
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.